Publications by authors named "J M Zain"
Background: Effective treatment options are scarce for relapsed or refractory T-cell lymphoma. This study assesses the safety and activity of CTX130 (volamcabtagene durzigedleucel), a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured from healthy donor T cells, in patients with relapsed or refractory T-cell lymphoma.
Methods: This single-arm, open-label, phase 1 study was done at ten medical centres across the USA, Australia, and Canada in patients (aged ≥18 years) with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma, who had received at least one or at least two previous systemic therapy lines, respectively, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Background: Peripheral T-cell lymphomas are aggressive non-Hodgkin lymphomas with few treatment options for relapsed or refractory disease. Valemetostat tosylate (valemetostat) is a potent, novel, dual inhibitor of EZH2 and EZH1. We investigated the clinical activity and safety of valemetostat in patients with relapsed or refractory peripheral T-cell lymphoma, and its safety in patients with relapsed or refractory adult T-cell leukaemia/lymphoma.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are testing valemetostat, an EZH2 and EZH1 inhibitor, for safety and effectiveness in patients with relapsed or refractory non-Hodgkin lymphoma, due to limited treatment options and poor outcomes.
- The study involved 90 participants from 19 hospitals across Japan and the USA, who received varying doses of valemetostat in a phase 1 clinical trial to find the right dosage and assess its anti-tumor effects.
- Initial findings will help determine the most effective dosages and provide insights into the drug's safety profile, with a majority of patients having peripheral T-cell lymphoma.
Background: Prognostic models in peripheral T cell lymphoma (PTCL) have identified biological factors including age, performance status, LDH, and BM involvement as prognostic for survival. The association of social determinants of health (SDH), on PTCL outcomes remains unexplored.
Methods: To evaluate the impact of actionable SDH on PTCL mortality across race groups, we conducted a retrospective cohort study that included all White, Hispanic, Asian/Pacific Islander (PI) and Black adult patients with nodal PTCLs , diagnosed 2000-2020, in California.
Article Synopsis
- Epstein-Barr Virus (EBV) positive primary cutaneous marginal zone lymphoma (PCMZL) is rare and can transform into more aggressive forms, like plasmablastic lymphoma (PBL), which is often fatal.
- The case discussed involves a patient with multifocal PCMZL who experienced a sequence of transformations, eventually leading to disease progression and death, despite various treatments, with genetic mutations similar across lymphomas indicating a common origin.
- A review of 18 cases shows that nearly half of patients with transformed PCMZL succumbed to the disease, particularly those diagnosed with multiple disease sites, highlighting the poor prognosis associated with this transformation.